Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades

Abstract

The incidence of ES has not increased appreciably over the last 30 years. A marked decrease in the proportion of unstaged cases may be reflective of diagnostic improvement or changes in reporting. There is a clear improvement in survival for both localized and metastatic disease. Poorer outcome of metastatic patients still warrants intensification of therapy, which is currently being tested in several ongoing trials.

Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults

“…When available, a positron emission tomography-computed tomography (PET-CT) was performed. 1 Induction chemotherapy consisted of six VIDE courses. 13 APHP was the preferred graft source.…”

“…Grades 3-4 thrombocytopenia ( o50 000 m/m) lasted for a median duration of 37.5 days after Mel/Bu (versus 15 days after thiotepa).Three haemorrhagic complications occurred (retinal haemorrhage (n = 2), grade 3 haemorrhagic cystitis which required a platelet transfusion). 1 Digestive toxicity was predominantly mucositis (n = 6, 46%), lasting a median duration of 6 days after thiotepa and 12 days after Mel/Bu. Grade 1 and grade 3 veno-occlusive disease occurred exclusively after Mel/Bu in two patients (15%).…”

“…1 ES is characterised by a specific translocation t (11;22) and transcript EWS-Fli1. 2 Currently, in the field of multimodality therapy, event-free survival (EFS) rates have increased from 10% to 470% in localised disease.…”

Survival outcome among patients with Ewing’s sarcoma of bones and joints: a population-based cohort study

“…Additionally, most cases of Ewing's sarcoma of the bones and joints are found in the limbs, pelvis or spine. 4,8 Nonetheless, there is a lack of survival studies on Ewing's sarcoma arising in the bones and joints and associated prognostic factors, based on up-to-date data on nationwide populations.…”

“…It is considered to be a high-grade malignancy, ranking second in the list of malignant bone tumors. [1][2][3][4][5][6][7] It is commonly considered to be an extremely aggressive osteolytic cancer that usually occurs in the bones of the limbs and pelvis and it can metastasize to distant locations such as bone marrow, the lungs and other soft tissues at an early stage. 1,3,7 In the United States, the overall incidence rate of Ewing's sarcoma is approximately 0.1 case per 100,000 individuals per year, and this rate had not undergone any obvious change over past 30 years.…”